An experimental evaluation of the pharmacokinetics of fusidic acid in peritoneal dialysis

References

1. Heaton A., Rodger R. S. C., Sellars L. Continuous ambulatory peritoneal dialysis after the honeymoon: review of experience in Newcastle 1979-84. Br Med J 1986; 293:938–941
   [Google Scholar]
2. Nissenson A. R., Gentile D. E., Soderblom R. E., Oliver D. F., Brax C. the Medical Review Board, NCC #4, Los Angeles, California. Morbidity and mortality of continuous ambulatory peritoneal dialysis: regional experience and longterm prospects. Am J Kidney Dis 1986; 7:229–234
   [Google Scholar]
3. Glew R. H., Pavuk R. A., Shuster A., Alfred H. J. Vancomycin pharmacokinetics in patients undergoing chronic intermittent peritoneal dialysis. Int J Clin Pharmacol Ther Toxicol 1982; 20:559–563
   [Google Scholar]
4. Somani P., Shapiro R. S., Stockard H., Higgins J. T. Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis. Clin Pharm Ther 1982; 32:113–121
   [Google Scholar]
5. Blevins R. D., Halstenson C. E., Salem N. G., Matzke G. R. Phar macokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1984; 25:603–606
   [Google Scholar]
6. Boeschoten E. W., Rietra P. J. G. M., Krediet R. T., Visser M. J., Arisz L. CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine. J Antimicrob Chemother 1985; 16:789–797
   [Google Scholar]
7. Nolph K. D., Cutler S. J., Steinberg S. M., Novak J. W. Continuous ambulatory peritoneal dialysis in the United States: a three-year study. Kidney Int 1985; 28:198–205
   [Google Scholar]
8. Fenton S. S. A. The University of Toronto Collaborative Dialysis Group. Peritonitis related deaths among CAPD patients. Peritoneal Dialysis Bulletin 1983; 3: Suppl 9S–11S
   [Google Scholar]
9. Taylor G., Bloor K. Antistaphylococcal activity of fucidin. Lancet 1962; 1:935–937
   [Google Scholar]
10. Crosbie R. B. Treatment of staphylococcal infections with “fucidin”. Br Med J 1963; 1:788–794
    [Google Scholar]
11. Reeves D. S. Review—The pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987; 20:467–476
    [Google Scholar]
12. Saggers B. A., Lawson D. In vivo penetration of antibiotics into sputum in cystic fibrosis. Arch Dis Child 1968; 43:404–409
    [Google Scholar]
13. Sattar M. A., Barrett S. P., Cawley M. I. D. Concentrations of some antibiotics in synovial fluid after oral administration, with special reference to antistaphylococcal activity. Ann Rheum Dis 1983; 42:67–74
    [Google Scholar]
14. Saggers B. A., Lawson D. Some observations on the penetration of antibiotics through mucus in vitro. J Clin Pathol 1966; 19:313–317
    [Google Scholar]
15. Chater E. H., Flynn J., Wilson A. L. Fucidin levels in osteomyelitis. J Irish Med Assoc 1972; 65:506–508
    [Google Scholar]
16. Guttler F., Tybring L. Interaction of albumin and fusidic acid. Br J Pharmacol 1971; 43:151–160
    [Google Scholar]
17. McIntosh M. E., Smith W. G. J., Junor B. J. R., Forrest G., Brodie M. J. Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol 1985; 28:187–191
    [Google Scholar]
18. Walshe J. J., Morse G. D. Infectious complications of peritoneal dialysis. In Nissenson A. R. (eds) Clinical dialysis 2nd edn Norwalk: CT, Appleton & Lange; 1990301–318
    [Google Scholar]
19. Rubinstein E., Adam D., Moellering R., Waldvogel F. International symposium on new quinolones. Rev Infect Dis 1988; 10: Suppl1 S1–S271
    [Google Scholar]
20. Rose T. F., Ellis-Pegler R., Collins J., Small M. Oral pefloxacin mesylate in the treatment of continuous ambulatory peritoneal dialysis associated peritonitis: an open noncomparative study. J Antimicrob Chemother 1990; 25:853–859
    [Google Scholar]
21. MacGowan A. P., Greig M. A., Andrews J. M., Reeves D. S., Wise R. Pharmacokinetics and tolerance of a new film-coated tablet of sodium fusidate administered as a single oral dose to healthy volunteers. J Antimicrob Chemother 1989; 23:409–415
    [Google Scholar]
22. Verbist L. The antimicrobial activity of fusidic acid. J Antimicrob Chemother 1990; 25: Suppl B1–5
    [Google Scholar]
23. Jensen K., Lassen H. C. A. Combined treatment with antibacterial chemotherapeutical agents in staphylococcal infections. Q J Med 1969; 38:91–106
    [Google Scholar]
24. Rowling D. E. Further experience in the management of chronic osteomyelitis. J Bone Joint Surg 1970; 52B:302–307
    [Google Scholar]
25. Cartwright R. Y., Hall G. H. Management of shunt infection. Br Med J 1972; 4:46
    [Google Scholar]
26. Liddy N. Intravenous fusidic acid in the newborn. Lancet 1973; 1:621
    [Google Scholar]
27. Kanski J. J. Treatment of late endophthalmitis associated with filtering blebs. Arch Ophthalmol 1974; 91:339–343
    [Google Scholar]
28. Deodhar S. D., Russell F., Dick W. C., Nuki G., Buchanan W. W. Penetration of sodium fusidate (fucidin) in the synovial cavity. Scand J Rheumatol 1972; 1:33–39
    [Google Scholar]
29. de Louvois J., Gortvai P., Hurley R. Antibiotic treatment of abscesses of the central nervous system. Br Med J 1977; 2:985–987
    [Google Scholar]
30. Evans R. C., Holmes C. J. Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer. Antimicrob Agents Chemother 1987; 31:889–894
    [Google Scholar]